The use of inhibitors to target the vascular endothelial growth factor (VEGF) has been investigated in subjects harboring sarcomas and was especially convincing in treating angiosarcomas, given the high rate of VEGF expression in these neoplasms [28,29,30,31,32]. Here, VEGFA is linked to sarcoma.